Leuprolide Acetate
Leuprolide Acetate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Leuprolide Acetate; Generic name: LEUPROLIDE ACETATE; Manufacturer: Avenacy, LLC.
| Brand name | Leuprolide Acetate |
|---|---|
| Generic name | LEUPROLIDE ACETATE |
| Manufacturer | Avenacy, LLC |
| Used for | INDICATIONS AND USAGE Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. |
| Dosage | DOSAGE AND ADMINISTRATION The recommended dose is 1 mg (0.2 mL or 20 unit mark) administered as a single daily subcutaneous injection. As with other drugs administered chronically by subcutaneous injection, the injection site should be varied periodically. Each 0.2 mL contains 1 mg of leuprolide acetate, sodium chloride for tonicity adjustment, 1.8 mg of benzyl alcohol as preservative and water for injection. The pH may have been adjusted with sodium hydroxide and/or acetic acid. Follow the pict |
| Warnings | WARNINGS Initially, leuprolide acetate, like other LH-RH agonists, causes increases in serum levels of testosterone. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may occasionally develop during the first few weeks of leuprolide acetate treatment. A small number of patients may experience a temporary increase in bone pain, which can be managed symptomatically. As with other LH-RH agonists, isolated cases of ureteral obstruction and spinal |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15003c37-6e91-4c79-a85c-3d03343b53f9 |